Related Experiment Video
Updated: Oct 20, 2025
A Melanoma Patient-Derived Xenograft Model
Published on: May 20, 2019
Anti-Cancer Effects of Cyclic Peptide ALOS4 in a Human Melanoma Mouse Model
Bar Levi1, Shiri Yacobovich1, Michael Kirby1
1Department of Molecular Biology, Faculty of Natural Sciences, Ariel University, Ariel 4070000, Israel.
Abstract:
We examined the effects of ALOS4, a cyclic peptide discovered previously by phage library selection against integrin αvβ3, on a human melanoma (A375) xenograft model to determine its abilities as a potential anti-cancer agent. We found that ALOS4 promoted healthy weight gain in A375-engrafted nude mice and reduced melanoma tumor mass and volume. Despite these positive changes, examination of the tumor tissue did not indicate any significant effects on proliferation, mitotic index, tissue vascularization, or reduction of αSMA or Ki-67 tumor markers. Modulation in overall expression of critical downstream αvβ3 integrin factors, such as FAK and Src, as well as reductions in gene expression of c-Fos and c-Jun transcription factors, indirectly confirmed our suspicions that ALOS4 is likely acting through an integrin-mediated pathway. Further, we found no overt formulation issues with ALOS4 regarding interaction with standard inert laboratory materials (polypropylene, borosilicate glass) or with pH and temperature stability under prolonged storage. Collectively, ALOS4 appears to be safe, chemically stable, and produces anti-cancer effects in a human xenograft model of melanoma. We believe these results suggest a role for ALOS4 in an integrin-mediated pathway in exerting its anti-cancer effects possibly through immune response modulation.
Insights
ALOS4, a cyclic peptide, demonstrated anti-cancer effects by reducing melanoma tumor size and volume in mice. This peptide appears safe and stable, potentially acting through an integrin-mediated pathway.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Integrin αvβ3 is a key target in cancer therapy.
- Phage library selection identified ALOS4 as a peptide targeting integrin αvβ3.
- Melanoma xenograft models are crucial for evaluating anti-cancer agents.
Purpose of the Study:
- To evaluate the anti-cancer potential of ALOS4 in a human melanoma xenograft model.
- To investigate the mechanism of action of ALOS4.
- To assess the safety and stability of ALOS4.
Main Methods:
- Administration of ALOS4 to nude mice bearing human melanoma (A375) xenografts.
- Monitoring of tumor growth, volume, and animal weight.
- Analysis of tumor tissue for proliferation, vascularization, and specific markers (αSMA, Ki-67).
- Assessment of downstream integrin signaling pathway components (FAK, Src, c-Fos, c-Jun).
- Evaluation of ALOS4 formulation stability and material compatibility.
Main Results:
- ALOS4 promoted healthy weight gain and reduced melanoma tumor mass and volume.
- No significant changes were observed in tumor proliferation, mitotic index, or vascularization.
- Modulation of downstream integrin factors (FAK, Src) and transcription factors (c-Fos, c-Jun) suggested an integrin-mediated pathway.
- ALOS4 exhibited no formulation issues and demonstrated stability under storage.
Conclusions:
- ALOS4 exhibits anti-cancer effects in a human melanoma xenograft model.
- The mechanism of action likely involves an integrin-mediated pathway, possibly modulating immune responses.
- ALOS4 is a safe and chemically stable compound with therapeutic potential for melanoma.
